Memoks 10 tab. of p/o of 10 mg No. 60

Tablets of Memoks it is shown in Alzheimer's disease from light severity to severe forms.

Structure

Active ingredient: memantin;

1 tablet supports a memantin of a hydrochloride of 10 mg or 20 mg;

Excipients: lactose, cellulose microcrystalline, talc, silicon dioxide colloidal, magnesium stearate;

Mix for a film covering: lactose, a gipromelloza, the titan dioxide (E 171), polyethyleneglycol 4000 (macrogoal), for tablets of 20 mg ferrous oxide yellow (E 172), ferrous oxide red (E 172).

Contraindication

Hypersensitivity to active ingredient or to any component of drug.

Route of administration

under observation of the doctor, and only on condition of presence of the trustee who will regularly control administration of medicament by the patient.

should take the Drug 1 time a day every day at the same time. Tablets can be applied together with food or irrespective of meal.

Feature of use

Pregnant

Drug should not be used during pregnancy, except for the cases caused by accurate and obvious need.

Children

not to use Drug to children in connection with insufficiency of data on safety and efficiency.

Alzheimer's disease from moderately severe to severe forms usually leads

to deterioration in an opportunity to drive the car and disturbance of ability to work with mechanisms. Also, memantin has insignificant or moderate influence on the speed of response of the person therefore ambulatory patients should be warned about need of respect for extra care at control of motor transport or work with the equipment.

Overdose

Experience is limited to

.

Rather considerable overdoses (200 mg and 105 mg within 3 days respectively) were or are connected with symptoms of increased fatigue, weakness and/or diarrhea, or had an asymptomatic course. At overdose up to 140 mg or unspecified a dose observed symptoms of disturbance of the central nervous system (confusion, slackness, drowsiness, dizziness, excitement, aggression, hallucinations, disturbances of gait) and/or gastrointestinal disturbances (vomiting and diarrhea). After reception of 2000 mg of a memantin at the patient the coma within 10 days, later - a diplopia and excitement developed. After symptomatic treatment and a plasma exchange ​​ the patient recovered without consequences.

symptomatic treatment, specific antidote does not exist. It is necessary to use standard clinical procedures for removal of active ingredient from an organism, for example gastric lavage, intake of activated carbon, urine reaction acidulation methods, an artificial diuresis. In case of excessive general stimulation of the central nervous system the symptomatic treatment should be performed with care.

Side effects

• from the immune system: often - hypersensitivity.
• from mentality: often - drowsiness; infrequently - confusion of consciousness, a hallucination; uncertain - psychotic reactions.
• from nervous system: often - dizziness, balance disturbance; infrequently - disturbance of gait; very seldom - convulsive attacks.
• from heart: infrequently - heart failure.
• from vessels: often - arterial hypertension; infrequently - venous thrombosis / tromboembolizm.
• from a respiratory system: often - an asthma.
• from digestive tract: often - a constipation; infrequently - vomiting; uncertain - pancreatitis.
• from a liver and biliary tract: often - increase in indicators of function of a liver; uncertain - hepatitis.

Interaction

Should avoid simultaneous use of a memantin and an amantadin because of risk of developing pharmakotoksichesky psychosis. Both connections are chemically connected NMDA antagonists. The same can concern also ketamine and dextromethorphan.

developing of psychosis given concerning risk at combined use of a memantin and Phenytoinum Exists.

to Store

out of children's reach, in original packing at a temperature not above 25 °C.

Expiration date - 2 years.